

Attachment B

May 10, 2017

Amgen USA Inc. (Amgen) has completed the issuance of credits (effectuated by Apexus, LLC) to covered entities impacted by the adjustment to Amgen's 340B ceiling price for Epogen® (Epoetin alfa), Neulasta® (pegfilgrastim), Neupogen® (Filgrastim), Vectibix® (panitumumab), Nplate® (romiplostim), Prolia® (denosumab), and Sensipar® (cinacalcet) NDCs for the timeframe first quarter 2011 through first quarter 2015 and for Aranesp® (darbepoetin alfa) and Enbrel® (etanercept) for the timeframe fourth quarter 2006 through first quarter 2015. Any questions from covered entities regarding these refunds should be directed to 340BRelations@amgen.com.